Re arthritis - one of my concerns:
Inflammatory Nanoparticles Discovered In Joint Fluid Of Arthritis Patients, Based On Methods Pioneered by Nanobac Pharmaceuticals' Scientists
BUSINESS WIRE - May 03, 2006 11:50 AM US Eastern Timezone
"This is the first report to indicate that human synovial fluids contain Nanobacteria-like particles," the study notes.
TAMPA, Fla.--(BUSINESS WIRE)--May 3, 2006--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") today announced that Inflammatory nanoparticles that produce calcified deposits like those found in arthritic joints have been cultured from the synovial fluid of rheumatoid arthritis and osteoarthritis patients by Japanese researchers, as reported in the Journal of Proteome Research.
"This is the first report to indicate that human synovial fluids contain Nanobacteria-like particles," the study notes.
The study, Nanobacteria-Like Particles in Human Arthritic Synovial Fluids, by T. Tsurumoto, T. Matsumoto, A. Yonekura, and H. Shindo, Department of Orthopaedics, Graduate School of Biomedical Sciences, Nagasaki University, supports the existence and pathogenic role of nanobacteria-like particles found in human diseases such as heart, prostate and kidney disease by Mayo Clinic and other researchers.
In a two year experiment, calcifying nanoparticles were cultured from the joint fluid of each participating patient, demonstrating that 100 percent of patients had the particles.
The experiment was based on methods pioneered by Nanobac Scientists, Drs. Neva Ciftcioglu and Olavi Kajander.
"After about 2 months of culture, nanoparticles appeared in the synovial fluids from all the patients to greater or lesser degrees," the study found. "These nanoparticles gradually increased in number and in size."
Medical researchers have often theorized about the presence of a calcifying agent that generates associated painful inflammation in arthritis, but until now had never found one.
Nanobacteria produce a calcium phosphate material known as calcification, which is shown in many studies, and cited in the Merck Manual of Diagnosis and Therapy, as provoking inflammation.
"If self-proliferating nanoparticles exist in mammalian synovial fluids and membranes, then they may have an effect on many joint diseases," the study's authors concluded.
"This is another example of independent researchers finding nanobacteria in patients with a specific disease condition," said Nanobac Co-Chairman Dr. Benedict Maniscalco, Fellow of the American College of Cardiology (FACC).
"It shows the value of our research, which is the only work to explain how calcification occurs in diseases afflicting most of the aging population," Dr. Maniscalco added.
The findings come on the heels of a paper published in the World Journal of Urology by Cleveland Clinic researcher Dr. Daniel Shoskes and Dr. Hadley M. Wood, which concluded that nanobacteria-like particles may play a ubiquitous role in prostate disease.
Another independent paper published earlier this year in the journal Urology Research by Khullar et al reports induction of renal calcification by nanobacteria.
Disclosure statement: Nanobac Pharmaceuticals did not fund the arthritis or Khullar studies, so the findings are independent.
Link to study abstract at: nanobac.com
About Nanobac Pharmaceuticals
Nanobac Pharmaceuticals, Inc. is a life science company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles, otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.
Nanobac's drug discovery and development is focused on developing new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for the detection of Calcifying Nanoparticles. IVD products include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the Nano-Vision(TM) line of antibodies and reagents. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: nanobac.com.
nsti.org
Ref:
J. Proteome Res., 5 (5), 1276 -1278, 2006. 10.1021/pr050450w S1535-3893(05)00450-1
Web Release Date: April 8, 2006
Copyright © 2006 American Chemical Society
Nanobacteria-Like Particles in Human Arthritic Synovial Fluids
T. Tsurumoto,* T. Matsumoto, A. Yonekura, and H. Shindo
Department of Orthopaedics, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki, 852-8501, Japan
Received December 10, 2005
Abstract:
We investigated the existence of nanosize particles in synovial fluids of rheumatoid arthritis and osteoarthritis patients. These specimens were cultured under mammalian cell culture conditions (37 C; 5% CO2/95% air) for a long period. After about 2 months, many nanoparticles appeared and they gradually increased in number and in size. The nanobacteria-like particles exist in synovial fluids of arthritis patients. The possibility of their existence and pathogenesis in various diseases should be verified cautiously.
Keywords: nanobacteria arthritis synovial fluid rheumatoid arthritis osteoarthritis microorganisms
pubs.acs.org |
